
AbVitro
AbVitro, a spinout from George Church’s lab at Harvard University.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
$125m Valuation: $125m | Acquisition | ||
Total Funding | 000k |

Related Content
AbVitro, a spinout from George Church’s lab at Harvard University, is a therapeutic target discovery company. It offers a technology platform that leverages natural immune responses to address diseases with unmet medical needs. The company's technology allows for the identification of full-length, natively paired antibodies and T cell receptors.
This technology is used to identify novel therapeutic targets and antibodies for cancer, autoimmune, and infectious diseases. The company's intellectual property includes 21 registered patents, primarily in the 'Medical or Veterinary Science; Hygiene' category.
AbVitro was acquired by Juno Therapeutics. Prior to the acquisition, the company was funded by Sante Ventures.
Keywords: therapeutic targets, antibody discovery, immune sequencing, cancer, autoimmune diseases, infectious diseases, T cell receptors, medical patents, Juno Therapeutics, Sante Ventures